Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Mem. Inst. Oswaldo Cruz ; 106(5): 594-605, Aug. 2011. ilus, graf
Article in English | LILACS | ID: lil-597720

ABSTRACT

Flaviviruses cause severe acute febrile and haemorrhagic infections, including dengue and yellow fever and the pathogenesis of these infections is caused by an exacerbated immune response. Dendritic cells (DCs) are targets for dengue virus (DENV) and yellow fever virus (YF) replication and are the first cell population to interact with these viruses during a natural infection, which leads to an induction of protective immunity in humans. We studied the infectivity of DENV2 (strain 16681), a YF vaccine (YF17DD) and a chimeric YF17D/DENV2 vaccine in monocyte-derived DCs in vitro with regard to cell maturation, activation and cytokine production. Higher viral antigen positive cell frequencies were observed for DENV2 when compared with both vaccine viruses. Flavivirus-infected cultures exhibited dendritic cell activation and maturation molecules. CD38 expression on DCs was enhanced for both DENV2 and YF17DD, whereas OX40L expression was decreased as compared to mock-stimulated cells, suggesting that a T helper 1 profile is favoured. Tumor necrosis factor (TNF)-α production in cell cultures was significantly higher in DENV2-infected cultures than in cultures infected with YF17DD or YF17D/DENV. In contrast, the vaccines induced higher IFN-α levels than DENV2. The differential cytokine production indicates that DENV2 results in TNF induction, which discriminates it from vaccine viruses that preferentially stimulate interferon expression. These differential response profiles may influence the pathogenic infection outcome.


Subject(s)
Humans , Cytokines/biosynthesis , Dendritic Cells/immunology , Dengue Virus/immunology , Dengue/immunology , Yellow Fever/immunology , Yellow fever virus/immunology , Biomarkers , Cell Differentiation , Chemokines/biosynthesis , Dendritic Cells , Dengue Vaccines/immunology , Dengue Virus/physiology , Dengue , Interferon-alpha/immunology , Interferon-alpha , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha , Virus Replication , Yellow Fever Vaccine/immunology , Yellow Fever , Yellow fever virus/physiology
3.
Arq. neuropsiquiatr ; 66(3b): 678-684, set. 2008. tab
Article in English | LILACS | ID: lil-495532

ABSTRACT

Neuromyelitis optica (NMO) is an inflammatory, demyelinating disease of the central nervous system characterized by the association of a serious myelitis and unilateral or bilateral optic neuritis. The present study aimed to analyze the immunological parameters of NMO patients with diagnosis established based on Wingerchuck et al. (1999) criteria. Production of IgG and IgA antibodies to antigens of MBP, PLP 95-116, MOG 92-106, and the cytokines interleukin-4 (IL-4) and interferon-γ (INF-γ) were assessed by Elisa assay. The cohort was formed by 28 NMO patients and a matched healthy control group. NMO patients had significant high levels of IgG to MOG (p<0.0001), PLP (p=0.0002) and MBP (p<0.0001), and solely IgA to MBP (p<0.0001). INF-γ (p=0.61) levels were similar to healthy controls. Increased production of IL-4 (p=0.0084) indicates an important role for this cytokine in the activation of Th2 regulatory cells and of the IgA producers B lymphocyte indicating activation of humoral immunity.


A neuromielite óptica (NMO) é doença inflamatória do sistema nervoso central, caracterizada por mielite aguda ou subaguda grave e neurite óptica unilateral ou bilateral. Este estudo objetiva analisar parâmetros imunológicos de pacientes com critérios de Wingerchuck et al. (1999) para NMO. O método de ELISA avaliou a produção de IgG e IgA para antígenos da proteína básica da mielina (MBP), o proteolipídeo (PLP) 95-116, a glicoproteina associada ao oligodendrócito (MOG) 92-106 e as citocinas interleucina-4 (IL-4) e interferon-gama (INF-γ). Foram incluνdos 28 pacientes com NMO pareados com controles saudáveis. Pacientes com NMO apresentaram níveis significativamente elevados de imunoglobulinas reativas dos isotipos IgG para MOG (p<0,0001), PLP (p=0,0002) e MBP (p<0,0001) e IgA somente para MBP (p<0,0001). Os níveis de INF-γ (p=0,61) foram semelhantes aos controles. A produção elevada de IL-4 (p=0,0084) indica papel importante na ativação de células regulatórias Th2 e linfócitos B produtores de IgA e da ativação da imunidade humoral.


Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Biomarkers/blood , Immunoglobulin A/immunology , Immunoglobulin G/immunology , Interferon-alpha/immunology , /immunology , Myelin Proteins/immunology , Neuromyelitis Optica/immunology , Autoantigens/immunology , Enzyme-Linked Immunosorbent Assay , Immunoglobulin A/blood , Immunoglobulin G/blood , Interferon-alpha/blood , /blood , Myelin Proteins/blood , Neuromyelitis Optica/blood , Young Adult
4.
Acta odontol. latinoam ; 21(2): 153-158, 2008. tab, graf
Article in English | LILACS | ID: lil-546716

ABSTRACT

Streptococcus mutans (S. mutans) es el principal agente etiologico de la caries dental. Las proteínas PAc y glucosiltransferasas (GTFs) son factores de virulencia de este microorganismo relacionados con su fisiopatogenia y han sido usados en investigaciones de una vacuna para la caries dental. El objetivo de este estudio fue observar si GTFs (1301-1322) tiene la capacidad de activar las células T CD4+ en CMSP de humanos naturalmente sensibilizados, identificar el tipo de respuesta y establecer su relación con la caries dental. 30 individuos clasificados en los siguientes 3 grupos, fueron estudiados: caries activa (AC), historia de caries (HC) y libres de caries (H). Muestras de sangre fueron tomadas de cada individuo. La estimulación antígeno específico y la citometría de flujo fueron usadas para determinar las células productoras de citoquina IFN-y (citoquinas tipo 1) e IL-13 (citoquinas tipo 2). Se encontró respuesta de memoria celular frente a GTF-I (1301-1322) en humanos naturalmente sensibilizados. Tres tipos de respuesta fueron detectados: TH0, TH1 y NR. Se encontró un mayor porcentaje de LTCD4+ productores de IFN-y que de IL-13 (p=0.006). No se encontraron diferencias estadísticamente significativas para las otras variables estudiadas para los tres grupos (p<0.05). Se concluye que la respuesta inmune celular específica frente al péptido sintético GTF-I (1301-1322) de S, mutans, no es diferente entre los individuos sensibilizados naturalmente, resistentes a caries y con caries.


Subject(s)
Humans , Adolescent , Adult , Dental Caries/immunology , Dental Caries/microbiology , Cytokines/immunology , /immunology , Bacterial Proteins/immunology , Antigens, CD/immunology , /immunology , Antigens, Differentiation, T-Lymphocyte/immunology , Immunization , /immunology , Interferon-alpha/immunology , /analysis , Lymphocyte Activation , Leukocytes, Mononuclear/immunology , T-Lymphocytes/immunology
5.
Rev. medica electron ; 29(6)nov.-dic. 2007. tab
Article in Spanish | LILACS | ID: lil-488338

ABSTRACT

El Interferón es un conjunto de proteínas que se producen principalmente frente a un estímulo viral, también favorece y promueve otros mecanismos inmunológicos por lo cual es considerado una Citoquina, siendo el uso más frecuente, el terapéutico, en aquellas enfermedades donde se sospeche un origen principalmente viral. Desde su descubrimiento en el año 1957, el uso terapéutico es en afecciones las cuales se sospeche un origen viral y el cáncer, siendo más limitado su empleo como estimulador del Sistema Inmunológico. En el presente trabajo hemos tomado un grupo de estudio constituido por 362 pacientes al cual se le aplicó el Interferòn por vía tópica comparado con un Grupo control formado por 343 pacientes tratados con la terapéutica convencional durante 10 años de tratamiento. A ambos grupos se les habían diagnosticado diversas afecciones Virales de Piel y Mucosas y fueron tratados por un espacio de 10 años, tomándose una muestra inicial antes del tratamiento y posterior al mismo con intervalos de 1, 3, 6,12 meses y a los dos años de iniciado el tratamiento, comparándose algunos parámetros de la respuesta inmunológica, detectándose posteriormente en el grupo de estudio un aumento de la Inmunidad Humoral Sistémica, una remisión de los síntomas de más de 6 años y pocas reacciones colaterales.


The Interferon is a group of proteins, produced mainly against a viral stimulus; it also favors and promotes other immunologic mechanisms and that is why it is considered a cytokine, being its most frequent use, therapeutic, mainly in diseases of suspected viral origin. Since it was discovered in 1957, it has been therapeutically used in affections of suspected viral origins and cancer, being more limitedly used as a stimulator of the Immunological System. In our work we had a study group composed by 362 patients, who received Interferon by topical way, compared to a control group of 343 patients treated with conventional therapy during 10 years. Both groups were diagnosed with various viral affections of the skin and the mucous membrane. They were treated during 10 years, taking a sample before the treatment began and at the end of the 1 st , 3 rd , 6 th , 12 th months and the 2 nd year after the beginning of the treatment. Some parameters of the immunologic answer were compared, detecting in the study group an increase of the Systemic Humoral Immunity, a remission of the more-than-6-years symptoms and few side effects.


Subject(s)
Humans , Condylomata Acuminata/drug therapy , Stomatitis, Aphthous/drug therapy , Herpes Simplex/drug therapy , Herpes Zoster/drug therapy , Interferon-alpha/immunology , Interferon-alpha/therapeutic use , Antiviral Agents , Antibody Formation
6.
Rev. Soc. Bras. Med. Trop ; 38(supl.2): 92-95, 2005. tab, graf
Article in Spanish | LILACS | ID: lil-444168

ABSTRACT

Fetal/Neonatal immune responses are generally considered to be immature and weaker than in adults. We have sudied the cord blood T-cells of newborns congenitally-infected whith Tripanosoma cruzi, the protozoan agent of Chagas' disease. Our data demonstrate a predominant activation of CD8 T-cells expressing activation markers and armed to mediate effector functions. Indeed, we have detected parasite-specific CD8 T-cells secreting interferon-ã. Such response is enchanced in the presence of rIL-15. These findings point out that the fetal immune system is more competent than previously appreciated, since fetuses exposed to live pathogens are able to develop an adult-like immune CD8 T-cell response.


Subject(s)
Humans , Animals , Infant, Newborn , /immunology , Fetus/immunology , Trypanosoma cruzi , Apoptosis , Cell Differentiation/immunology , Cytokines/analysis , Flow Cytometry , Fetal Blood/cytology , Fetal Blood/immunology , Fetal Blood/parasitology , Immunity, Cellular , Interferon-alpha/immunology , Receptors, Antigen, T-Cell, alpha-beta/immunology , Trypanosoma cruzi/immunology
7.
Bol. Col. Mex. Urol ; 13(1): 11-3, ene.-abr. 1996. ilus
Article in Spanish | LILACS | ID: lil-181548

ABSTRACT

El adenocarcinoma renal metastásico es una neoplasia incurable. Una proporción de 50 por ciento de estas neoplasias se presentan como enfermedad avanzada con una mortalidad aproximada del 75 por ciento a un año. En este artículo se analizan la evolución de las metástasis pulmonares y los principales efectos secundarios en pacientes tratados con interferón alfa 2B en forma ambulatoria. Entre enero de 1993 y marzo de 1994 se trataron seis pacientes con diagnóstico de cáncer renal y metástasis pulmonares, cuatro varones y dos mujeres, con edades de 45 a 64 años. Se les administró interferón alfa 2B a la dosis de tres millones de UI por vía subcutánea, tres veces por semana, por un mínimo de seis meses. Todos los pacientes estaban vivos al año de seguimiento, en dos la enfermedad permaneció estable y en cuatro hubo progresión de la misa. Los enfermos toleraron en forma adecuada el medicamento, y en ningún caso hubo necesidad de suspender el tratamiento por efectos secundarios


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Immunologic Factors , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Interferon-alpha/immunology , Interferon-alpha/therapeutic use , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Kidney Neoplasms/therapy , Neoplasm Metastasis/immunology , Neoplasm Metastasis/pathology , Kidney/pathology
SELECTION OF CITATIONS
SEARCH DETAIL